Immune OTC Stock Alpha and Beta Analysis

IMUN -  USA Stock  

USD 1.75  0.00  0.00%

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immune Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immune Therapeutics over a specified time horizon. Remember, high Immune Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Please see Immune Therapeutics Backtesting, Immune Therapeutics Valuation, Immune Therapeutics Correlation, Immune Therapeutics Hype Analysis, Immune Therapeutics Volatility, Immune Therapeutics History and analyze Immune Therapeutics Performance.
Please note that although Immune Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, Immune Therapeutics did 0.59  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Immune Therapeutics stock's relative risk over its benchmark. Immune Therapeutics has a beta of 3.10  . Let's try to break down what Immune's beta means in this case. As returns on the market increase, returns on owning Immune Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Immune Therapeutics is expected to outperform it.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

Immune Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immune Therapeutics market risk premium is the additional return an investor will receive from holding Immune Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immune Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immune Therapeutics' performance over market.
α0.59   β-3.1
90 days against DJI

Immune Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immune Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Immune Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Immune Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Immune Therapeutics otc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immune Therapeutics shares will generate the highest return on investment. By understating and applying Immune Therapeutics otc stock market price indicators, traders can identify Immune Therapeutics position entry and exit signals to maximize returns.

Immune Therapeutics Return and Market Media

The median price of Immune Therapeutics for the period between Wed, Feb 16, 2022 and Tue, May 17, 2022 is 1.6 with a coefficient of variation of 12.13. The daily time series for the period is distributed with a sample standard deviation of 0.19, arithmetic mean of 1.6, and mean deviation of 0.15. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
CIDARA THERAPEUTICS, INC. Managements Discussion and Analysi...03/07/2022
Aileron Therapeutics Reports Fourth Quarter and Full Year 20...03/28/2022
Purchase by Gostanian Richard of 20000 shares of Immune Ther...04/01/2022
Agenus Presents Data on AGEN1571 at AACR and Announces IND C...04/08/2022
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clini...04/12/2022
Statera Biopharma and Coeptis Therapeutics Announce Strategi...04/18/2022
Enzolytics Inc Major Reversal Brewing as Biotech Gains Tract...04/21/2022
Statera Biopharma and Immune Therapeutics Inc. Announce Stra...04/27/2022
Hot Penny Stocks To Buy For Under 1 This Week - Penny Stocks05/03/2022
Statera Biopharma sells rights to addiction-treatment drug, ...05/06/2022

About Immune Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all equity instruments such as Ford or other stocks, funds, and ETFs. Alpha measures the amount that position in Immune Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Immune Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Immune Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immune Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immune Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immune Therapeutics. Please utilize our Beneish M Score to check the likelihood of Immune Therapeutics' management manipulating its earnings.
Upcoming Quarterly Report21st of April 2020
Next Fiscal Quarter End31st of December 2019

Build Portfolio with Immune Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immune Therapeutics Backtesting, Immune Therapeutics Valuation, Immune Therapeutics Correlation, Immune Therapeutics Hype Analysis, Immune Therapeutics Volatility, Immune Therapeutics History and analyze Immune Therapeutics Performance. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Correlations
Find global opportunities by holding instruments from different markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Immune Therapeutics technical otc stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Immune Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Immune Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...